Intrawound Vancomycin Powder for Spine Tumor Surgery

Area of Science:

• Oncology
• Neurosurgery
• Infectious Disease

Background:

• Spine tumor surgery carries a risk of postsurgical infections.
• Intrawound vancomycin powder is increasingly used to prevent surgical site infections.
• The efficacy of intrawound vancomycin in spine tumor surgery requires further evaluation.

Purpose of the Study:

• To assess the infection rates associated with intrawound vancomycin powder application during spine tumor surgery.
• To investigate potential correlations between radiation therapy and postsurgical infections in this patient cohort.

Main Methods:

• Retrospective evaluation of prospectively collected data from spine tumor surgery patients (≥18 years) who received intrawound vancomycin powder.
• Data collected included patient demographics, tumor characteristics, surgical details, radiation therapy use, and infection rates up to 30 days postoperatively.
• Statistical analysis was performed to identify associations between variables and infection outcomes.

Main Results:

• A total of 35 patients (41 procedures) were analyzed.
• The overall culture-proven infection rate was 4.9% (2 out of 41 procedures).
• No significant association was found between radiation treatment (preoperative, postoperative, or both) and the occurrence of postsurgical infections (p=0.19).

Conclusions:

• Intrawound vancomycin powder application in spine tumor surgery is associated with a low infection rate of 4.9%.
• Radiation therapy, whether preoperative or postoperative, does not appear to correlate with an increased risk of postsurgical infections in patients undergoing spine tumor surgery with intrawound vancomycin.
• Further prospective studies are warranted to confirm these findings and optimize infection prevention strategies.